Cargando…

Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells

Purpose: We aimed at comparing the effects of omidenepag (OMD) with those of prostaglandin F (FP) receptor agonists (FP agonists) on adipogenesis in mouse 3T3-L1 cells. Methods: To evaluate the agonistic activities of OMD against the mouse EP2 (mEP2) receptor, we determined cAMP contents in mEP2 rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Yasuko, Taniguchi, Takazumi, Inazumi, Tomoaki, Iwamura, Ryo, Yoneda, Kenji, Odani-Kawabata, Noriko, Matsugi, Takeshi, Sugimoto, Yukihiko, Shams, Naveed K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175626/ https://www.ncbi.nlm.nih.gov/pubmed/31934812 http://dx.doi.org/10.1089/jop.2019.0079

Ejemplares similares

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice
por: Esaki, Yoshihiko, et al.
Publicado: (2020)

Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells
por: Kumon, Masashi, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
por: Aihara, Makoto, et al.
Publicado: (2019)

Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells
por: Ida, Yosuke, et al.
Publicado: (2020)

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
por: Olander, Kenneth W., et al.
Publicado: (2021)

Omidenepag, a Selective, Prostanoid EP2 Agonist, Does Not Suppress Adipogenesis in 3D Organoids of Human Orbital Fibroblasts
por: Hikage, Fumihito, et al.
Publicado: (2021)

Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study
por: Panarelli, Joseph F., et al.
Publicado: (2023)

Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study
por: Nakakura, Shunsuke, et al.
Publicado: (2021)

Essential role of prostaglandin E(2) and the EP3 receptor in lymphatic vessel development during zebrafish embryogenesis
por: Iwasaki, Ryo, et al.
Publicado: (2019)

Reactivities of a Prostanoid EP2 Agonist, Omidenepag, Are Useful for Distinguishing between 3D Spheroids of Human Orbital Fibroblasts without or with Graves’ Orbitopathy
por: Ida, Yosuke, et al.
Publicado: (2021)

Effects of selective EP2 receptor agonist, omidenepag, on trabecular meshwork cells, Schlemm’s canal endothelial cells and ciliary muscle contraction
por: Nakamura, Natsuko, et al.
Publicado: (2021)

Effect of Prostaglandin E2 Agonist Omidenepag on the Expression of Matrix Metalloproteinase in Trabecular Meshwork Cells
por: Kim, Jeong Yeub, et al.
Publicado: (2022)

Comparison of the Drug-Induced Efficacies between Omidenepag Isopropyl, an EP2 Agonist and PGF2α toward TGF-β2-Modulated Human Trabecular Meshwork (HTM) Cells
por: Suzuki, Soma, et al.
Publicado: (2022)

Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
por: Terao, Etsuko, et al.
Publicado: (2020)

Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension
por: Matsuo, Masato, et al.
Publicado: (2022)

Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension
por: Shiratori, Naka, et al.
Publicado: (2021)

Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2020)

One-Year Follow-Up Study of Changes in Prostaglandin-Associated Periorbital Syndrome After Switch From Conventional Prostaglandin F2alfa to Omidenepag Isopropyl
por: Oogi, Satomi, et al.
Publicado: (2020)

Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
por: Nakazawa, Toru, et al.
Publicado: (2022)

Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
por: Wirta, David L., et al.
Publicado: (2022)

The Roles Played by FP/EP3 Receptors During Pressure-lowering in Mouse Eyes Mediated by a Dual FP/EP3 Receptor Agonist
por: Yamagishi-Kimura, Reiko, et al.
Publicado: (2022)

Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepag Isopropyl 0.002% and Ripasudil 0.4%
por: Terao, Etsuko, et al.
Publicado: (2020)

Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan
por: Miki, Atsuya, et al.
Publicado: (2022)

Cystoid macular edema associated with omidenepag isopropyl in a phakic eye with an implantable collamer lens: a case report
por: Bae, Byung-Jin, et al.
Publicado: (2023)

Host Prostaglandin E(2)-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth
por: Amano, Hideki, et al.
Publicado: (2003)

Prostaglandin E(2) receptor Ptger4b regulates female-specific peptidergic neurons and female sexual receptivity in medaka
por: Fleming, Thomas, et al.
Publicado: (2022)

Rosiglitazone and a β(3)-Adrenoceptor Agonist Are Both Required for Functional Browning of White Adipocytes in Culture
por: Merlin, Jon, et al.
Publicado: (2018)

Prostaglandin F2 and EP2 Agonists Exert Different Effects on 3D 3T3-L1 Spheroids during Their Culture Phase
por: Ida, Yosuke, et al.
Publicado: (2021)

Sensitization of TRPV1 by EP(1 )and IP reveals peripheral nociceptive mechanism of prostaglandins
por: Moriyama, Tomoko, et al.
Publicado: (2005)

The Action of D-Dopachrome Tautomerase as an Adipokine in Adipocyte Lipid Metabolism
por: Iwata, Takeo, et al.
Publicado: (2012)

Simultaneous Use of ROCK Inhibitors and EP2 Agonists Induces Unexpected Effects on Adipogenesis and the Physical Properties of 3T3-L1 Preadipocytes
por: Ida, Yosuke, et al.
Publicado: (2021)

Pseudoginsenoside F11, a Novel Partial PPARγ Agonist, Promotes Adiponectin Oligomerization and Secretion in 3T3-L1 Adipocytes
por: Wu, Guoyu, et al.
Publicado: (2013)

Apparent histological changes of adipocytes after treatment with CL 316,243, a β-3-adrenergic receptor agonist
por: Ghorbani, Masoud, et al.
Publicado: (2015)

Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist
por: Goto, Tsuyoshi, et al.
Publicado: (2011)

Melanocortin agonists stimulate lipolysis in human adipose tissue explants but not in adipocytes
por: Møller, Cathrine Laustrup, et al.
Publicado: (2015)

Impaired adrenergic agonist-dependent beige adipocyte induction in obese mice
por: SHIN, Woongchul, et al.
Publicado: (2019)

Role of the PGE(2) receptor subtypes EP1, EP2, and EP3 in repetitive traumatic brain injury
por: Catlin, James, et al.
Publicado: (2019)

The prostaglandin receptor EP2 determines prognosis in EP3-negative and galectin-3-high cervical cancer cases
por: Dietlmeier, Sebastian, et al.
Publicado: (2020)

Resveratrol attenuates triglyceride accumulation associated with upregulation of Sirt1 and lipoprotein lipase in 3T3-L1 adipocytes
por: Imamura, Haruki, et al.
Publicado: (2017)

Inhibition of EP4 Signaling Attenuates Aortic Aneurysm Formation
por: Yokoyama, Utako, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_umgdilhdet975c56mud4oloie3